Abstract: Disclosed are compositions comprising chimeric antigen receptors (CARs) and related methods of use in cancer immunotherapy. Compositions include reprogrammed immune cells (e.g., macrophages, neutrophils, dendritic cells, and T cells) that are metabolically fit for tumor microenvironments. The engineered immune cells are reprogrammed to express one or more of recombinant CARs at their cell surfaces and are loaded with glycolysis accelerating metabolites (e.g., F16BP or succinate). Methods of treating a subject with a condition, such as cancer, are also disclosed and include administering an effective amount of a composition comprising an engineered immune cell to a subject in need thereof.

Abstract: Disclosed are systems, methods, and non-transitory computer-readable media for configuration of optical sensor devices in vehicles based on thermal data. To manage the temperature of an optical sensor device, temperature data describing the current temperature of the optical sensor is used to determine whether the current temperature meets or exceeds a predetermined threshold temperature. If the current temperature meets or exceeds the threshold temperature, the optical sensor device may be configured into a modified operating mode to reduce the current temperature of the optical sensor device. For example, the operating mode of the optical sensor device may be modified to terminate one or more processes, reduce a frame rate at which image/video data is captured, and the like.

Abstract: The present invention provides polymers, microparticles, nanoparticles, and compositions thereof for inducing an immune response and preventing or treating a metabolic inhibition in a subject. The present invention additionally provides kits that find use in the practice of the methods of the invention.

Abstract: The present invention provides polymers, particles, and compositions thereof that selectively and efficiently deliver various therapeutic agents, such as metabolites, to a cell. The present invention further relates to methods relating to the said polymers, particles, and compositions for enhancing biological tissue growth (e.g. biological tissue regeneration in wound healing) in a subject. The present invention additionally provides kits that find use in the practice of the methods of the invention.

Abstract: Disclosed are systems, methods, and non-transitory computer-readable media for configuration of optical sensor devices in vehicles based on thermal data. To manage the temperature of an optical sensor device, temperature data describing the current temperature of the optical sensor is used to determine whether the current temperature meets or exceeds a predetermined threshold temperature. If the current temperature meets or exceeds the threshold temperature, the optical sensor device may be configured into a modified operating mode to reduce the current temperature of the optical sensor device. For example, the operating mode of the optical sensor device may be modified to terminate one or more processes, reduce a frame rate at which image/video data is captured, and the like.

Abstract: The present invention relates to metabolite-based polymers and polymeric particles that serve as therapeutic agents, compositions comprising the same, and methods of use thereof.

Abstract: The present disclosure provides metabolite-based polymeric particles and methods for a modulating the intracellular metabolic-profile/pathways. For example, in one aspect, the disclosure relates to alpha-ketoglutarate (aKG)-based polymeric-microparticles and methods of use.

Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.

Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: A Fe(II)- and Ca+2-chelated alginate/gelatin conjugate.

Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.

Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.

Abstract: An agent comprising: an algin crosslinked with acetal linkages; and at least one cation coupled to the crosslinked algin.

Abstract: The present invention provides antigen-specific, tolerance-inducing microparticles for the targeted delivery of therapeutic agents to immune cells. In addition, the present invention allows for sustained release of therapeutic agents for a prolonged period of time. Also provided are therapeutic uses of the present invention for the prevention and/or treatment of immune diseases and autoimmune disorders. In a specific embodiment, the present invention provides treatment for type 1 diabetes.